Jubilant Therapeutics

Jubilant Therapeutics

  • Founded: 2019
  • Location: Bedminster, NJ
  • Employee range: 11 - 50
  • Clinical stage: Clin1/Clin2
  • Therapy area: neuroendocrine tumors
  • Drug types: ONC, IMM
  • Lead product: JBI-802
  • Product link: https://www.jubilanttx.com/pipeline/overview
  • Funding: not disclosed



job board

Short description:

Small Molecules

Drug notes:

JBI-778 Clin0 Sliceosome mutated tumors; JBI-2174 RD brain tumors; JBI-1044 RD oncology, autoimmune

Long description:

Jubilant Therapeutics is developing potent and selective small molecule modulators to address specific unmet medical needs in oncology and autoimmune diseases. Using their Therapeutic Index and Brain Exposure Optimization (TIBEO) discovery engine, Jubilant is integrating structure-based design and computational algorithms to discover and develop novel, precision therapeutics that have enhanced brain penetration. Jubilant’s lead candidate, JBI-802, targets an epigenetic modulator and is being tested for neuro-endocrine tumors.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com